LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 108

Suchoptionen

  1. Artikel: Medicines for long-term obesity management.

    Proietto, Joseph

    Australian prescriber

    2022  Band 45, Heft 2, Seite(n) 38–40

    Abstract: Obesity is always genetic or epigenetic in origin in an obesogenic environment. Dietary therapy is required for weight loss. Drugs to suppress hunger and increase satiety may assist while losing weight and are essential for most patients in the weight ... ...

    Abstract Obesity is always genetic or epigenetic in origin in an obesogenic environment. Dietary therapy is required for weight loss. Drugs to suppress hunger and increase satiety may assist while losing weight and are essential for most patients in the weight maintenance period. A combination of drugs may be needed. A personalised approach must be used when selecting the appropriate weight loss drug for the patient. This considers possible contraindications, the method of administration and adverse effects, and includes discussing the cost of the treatment. Several drugs do not have an approved indication in Australia for weight loss.
    Sprache Englisch
    Erscheinungsdatum 2022-04-01
    Erscheinungsland Australia
    Dokumenttyp Journal Article ; Review
    ZDB-ID 1075442-8
    ISSN 0312-8008
    ISSN 0312-8008
    DOI 10.18773/austprescr.2022.009
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 3233: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Obesity and Bone.

    Proietto, Joseph

    F1000Research

    2020  Band 9

    Abstract: Obesity and osteoporosis are both common conditions with high rates of morbidity and mortality. There is a relationship between obesity and bone. There are multiple factors that influence the risk of fracture, including the quality of bone, the risk of ... ...

    Abstract Obesity and osteoporosis are both common conditions with high rates of morbidity and mortality. There is a relationship between obesity and bone. There are multiple factors that influence the risk of fracture, including the quality of bone, the risk of falls, and the padding around the bone. These multiple factors partly explain the finding that obesity protects against fractures in some sites while increasing the risk in other parts of the body. While it is well known that increased weight builds bone, there are several mechanisms related to the obese state that make the bone more fragile. These include the increased production of bone marrow fat cells at the expense of bone-forming osteoblasts, an increase in inflammatory cytokines leading to the activation of bone-resorbing osteoclasts, mutations in the
    Mesh-Begriff(e) Alpha-Ketoglutarate-Dependent Dioxygenase FTO/genetics ; Bone and Bones/pathology ; Cellular Senescence ; Humans ; Obesity/physiopathology ; Osteoblasts/cytology ; Osteoclasts/cytology ; Osteocytes/cytology
    Chemische Substanzen Alpha-Ketoglutarate-Dependent Dioxygenase FTO (EC 1.14.11.33) ; FTO protein, human (EC 1.14.11.33)
    Sprache Englisch
    Erscheinungsdatum 2020-09-09
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2699932-8
    ISSN 2046-1402 ; 2046-1402
    ISSN (online) 2046-1402
    ISSN 2046-1402
    DOI 10.12688/f1000research.20875.1
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Our biology working against us in obesity: A narrative review on implications for management of osteoarthritis.

    Cicuttini, Flavia M / Proietto, Joseph / Lim, Yuan Z

    Osteoarthritis and cartilage open

    2023  Band 5, Heft 4, Seite(n) 100407

    Abstract: Obesity is the major modifiable risk factor for osteoarthritis (OA). A major focus of management in OA is weight loss. Although we live in an obesogenic environment, obesity has a predominantly genetic and epigenetic basis. This explains a person's ... ...

    Abstract Obesity is the major modifiable risk factor for osteoarthritis (OA). A major focus of management in OA is weight loss. Although we live in an obesogenic environment, obesity has a predominantly genetic and epigenetic basis. This explains a person's weight set point which is defended by biological mechanisms making weight loss difficult to achieve and maintain long term, regardless of the methods used. Significant weight regain occurs after weight loss, with weight tending to return to pre-treatment levels after cessation of interventions including the glucagon-like peptide-1 (GLP-1) agonists. An area that has received little attention is the slow, insidious weight creep of 0.5-1 kg/year over adulthood that sees individuals relentlessly increase weight. There is evidence that low intensity, personalised lifestyle interventions can prevent this weight creep, providing patients with achievable goals. In this narrative review, we examine the evidence for weight loss in OA, the biological mechanisms that make weight loss difficult to achieve and maintain and the potential negative impacts on patients. We review the evidence for preventing weight gain, the improvement in patient outcomes and the potential for significant healthcare savings through reduced knee replacements. We propose a combined approach of weight loss when indicated, together with targeting weight creep across adult years and the potential role of metformin. Implementing these combined approaches is likely to be more effective in improving patient related outcomes, reducing joint damage and healthcare costs, than our current focus on achieving weight loss in OA.
    Sprache Englisch
    Erscheinungsdatum 2023-09-09
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ISSN 2665-9131
    ISSN (online) 2665-9131
    DOI 10.1016/j.ocarto.2023.100407
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  4. Artikel: Obesity and weight management at menopause.

    Proietto, Joseph

    Australian family physician

    2017  Band 46, Heft 6, Seite(n) 368–370

    Abstract: Background: Many women report gaining weight as they transition through menopause. For most, the weight gain is modest and can be reduced with a conscious effort to limit energy intake and increase energy expenditure. However, many women who are already ...

    Abstract Background: Many women report gaining weight as they transition through menopause. For most, the weight gain is modest and can be reduced with a conscious effort to limit energy intake and increase energy expenditure. However, many women who are already overweight and obese will gain more weight as they approach menopause.
    Objective: The aims of this paper are to explain the reasons for menopausal weight gain and to detail a method for achieving and sustaining a substantial weight loss.
    Discussion: Weight gain during menopause is predominantly due to a reduction in spontaneous activity. For women who are lean, advice about controlling energy intake and increasing physical activity may be all that is required to prevent weight gain. For women who are overweight and obese rapid weight loss is best achieved with the help of a very low energy diet. This must be followed by lifelong behaviour modification with or without the help of hunger-suppressing pharmacotherapy.
    Sprache Englisch
    Erscheinungsdatum 2017-06
    Erscheinungsland Australia
    Dokumenttyp Journal Article
    ZDB-ID 423718-3
    ISSN 0300-8495
    ISSN 0300-8495
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 2235: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 27: Hefte anzeigen
    Zs.MO 642: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: Single-center real-life experience with testosterone treatment in adult men with Prader-Willi syndrome.

    Nolan, Brendan J / Proietto, Joseph / Sumithran, Priya

    American journal of medical genetics. Part A

    2022  Band 188, Heft 9, Seite(n) 2637–2641

    Abstract: Hypogonadism is the most frequent hormonal deficiency in individuals with Prader-Willi syndrome (PWS). This often necessitates testosterone treatment, but limited data are available to guide testosterone treatment in adult men with PWS. We aimed to ... ...

    Abstract Hypogonadism is the most frequent hormonal deficiency in individuals with Prader-Willi syndrome (PWS). This often necessitates testosterone treatment, but limited data are available to guide testosterone treatment in adult men with PWS. We aimed to evaluate the serum testosterone concentrations and adverse effects of testosterone treatment in individuals with PWS attending a specialist obesity management service. A retrospective audit was undertaken at Austin Health, Melbourne between January 2010 and April 2021. Main outcome measures were testosterone formulation and dose, serum total testosterone concentration, and prevalence of polycythemia and behavioral disturbance. Data were available for eight individuals with median baseline age 19 years (range, 19-42) and BMI 37 kg/m
    Mesh-Begriff(e) Adult ; Humans ; Hypogonadism/drug therapy ; Male ; Prader-Willi Syndrome/epidemiology ; Retrospective Studies ; Sleep Apnea, Obstructive ; Testosterone/adverse effects ; Young Adult
    Chemische Substanzen Testosterone (3XMK78S47O)
    Sprache Englisch
    Erscheinungsdatum 2022-05-09
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2108614-X
    ISSN 1552-4833 ; 0148-7299 ; 1552-4825
    ISSN (online) 1552-4833
    ISSN 0148-7299 ; 1552-4825
    DOI 10.1002/ajmg.a.62770
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1376/A: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: Intensive management of obesity in people with Prader-Willi syndrome.

    Nolan, Brendan J / Proietto, Joseph / Sumithran, Priya

    Endocrine

    2022  Band 77, Heft 1, Seite(n) 57–62

    Abstract: Purpose: Prader-Willi syndrome (PWS) is characterised by childhood-onset hyperphagia and obesity however limited data are available to guide treatment of obesity in this population. We aimed to evaluate the safety, tolerability, and efficacy of ... ...

    Abstract Purpose: Prader-Willi syndrome (PWS) is characterised by childhood-onset hyperphagia and obesity however limited data are available to guide treatment of obesity in this population. We aimed to evaluate the safety, tolerability, and efficacy of intensive medical weight loss interventions (very-low-energy diets [VLED] and/or pharmacotherapy) in individuals with PWS attending a specialist obesity management service.
    Methods: A retrospective audit was undertaken of individuals with PWS attending the Austin Health Weight Control Clinic between January 2010-April 2021. Main outcome measures were weight outcomes, duration of use, and adverse effects.
    Results: Data were available for 18 patients, of whom 15 were treated with intensive weight loss interventions. Median (interquartile range, IQR) age at baseline was 20 years (19-32) with median body weight 90 kg (75-118) and BMI 37 kg/m
    Conclusions: VLED and pharmacotherapy can achieve substantial weight loss in some individuals with PWS though non-adherence results in substantial weight regain. Adverse effects were ascribed to phentermine and topiramate, whereas liraglutide was well-tolerated in this population.
    Mesh-Begriff(e) Child ; Humans ; Liraglutide/therapeutic use ; Obesity/chemically induced ; Obesity/complications ; Obesity/therapy ; Phentermine/adverse effects ; Prader-Willi Syndrome/complications ; Prader-Willi Syndrome/drug therapy ; Retrospective Studies ; Topiramate/therapeutic use ; Weight Loss
    Chemische Substanzen Topiramate (0H73WJJ391) ; Liraglutide (839I73S42A) ; Phentermine (C045TQL4WP)
    Sprache Englisch
    Erscheinungsdatum 2022-05-07
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1194484-5
    ISSN 1559-0100 ; 1355-008X ; 0969-711X
    ISSN (online) 1559-0100
    ISSN 1355-008X ; 0969-711X
    DOI 10.1007/s12020-022-03064-1
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 3884: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel ; Online: GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates.

    Hryciw, Deanne H / Patten, Rhiannon K / Rodgers, Raymond J / Proietto, Joseph / Hutchinson, Dana S / McAinch, Andrew J

    Expert opinion on investigational drugs

    2024  Band 33, Heft 3, Seite(n) 183–190

    Abstract: Introduction: Type 2 diabetes (T2D) is metabolic disorder associated with a decrease in insulin activity and/or secretion from the β-cells of the pancreas, leading to elevated circulating glucose. Current management practices for T2D are complex with ... ...

    Abstract Introduction: Type 2 diabetes (T2D) is metabolic disorder associated with a decrease in insulin activity and/or secretion from the β-cells of the pancreas, leading to elevated circulating glucose. Current management practices for T2D are complex with varying long-term effectiveness. Agonism of the G protein-coupled receptor GPR119 has received a lot of recent interest as a potential T2D therapeutic.
    Areas covered: This article reviews studies focused on GPR119 agonism in animal models of T2D and in patients with T2D.
    Expert opinion: GPR119 agonists
    Mesh-Begriff(e) Animals ; Humans ; Diabetes Mellitus, Type 2/drug therapy ; Glucose/metabolism ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Incretins ; Insulin/metabolism ; Receptors, G-Protein-Coupled/agonists
    Chemische Substanzen Glucose (IY9XDZ35W2) ; GPR119 protein, human ; Hypoglycemic Agents ; Incretins ; Insulin ; Receptors, G-Protein-Coupled
    Sprache Englisch
    Erscheinungsdatum 2024-02-23
    Erscheinungsland England
    Dokumenttyp Review ; Journal Article
    ZDB-ID 1182884-5
    ISSN 1744-7658 ; 0967-8298 ; 1354-3784
    ISSN (online) 1744-7658
    ISSN 0967-8298 ; 1354-3784
    DOI 10.1080/13543784.2024.2321271
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 3739: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  8. Buch: Diabetes research

    Tuch, Bernard / Dunlop, Marjorie / Proietto, Joseph

    a guide for postgraduates

    2000  

    Verfasserangabe Bernard Tuch ; Marjorie Dunlop ; Joseph Proietto
    Sprache Englisch
    Umfang X, 128 S. : Ill.
    Verlag Harwood Acad. Publ
    Erscheinungsort Amsterdam
    Erscheinungsland Niederlande
    Dokumenttyp Buch
    HBZ-ID HT012852861
    ISBN 90-5702-461-6 ; 978-90-5702-461-0
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    SignaturLeihstatusStandort
    2000 A 5193 bestellbar zur Ausleihe Magazin

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  9. Artikel ; Online: Impact of starting BMI and degree of weight loss on changes in appetite-regulating hormones during diet-induced weight loss.

    Edwards, Kira-Ann L / Prendergast, Luke A / Kalfas, Stefanie / Sumithran, Priya / Proietto, Joseph

    Obesity (Silver Spring, Md.)

    2022  Band 30, Heft 4, Seite(n) 911–919

    Abstract: Objective: The aim of this study was to determine whether the hormone changes following weight loss are proportional to the degree of weight loss and to starting BMI.: Methods: A very low-energy diet was used to achieve 15% weight loss. Fasting and ... ...

    Abstract Objective: The aim of this study was to determine whether the hormone changes following weight loss are proportional to the degree of weight loss and to starting BMI.
    Methods: A very low-energy diet was used to achieve 15% weight loss. Fasting and postprandial gut hormones and leptin were measured during a meal test at baseline and at 5% (1%), 10% (2%), and 15% (2.5%) weight loss. Linear mixed-effects models were used to analyze hormone changes.
    Results: From baseline to 5% weight loss, decreases were seen in fasting concentrations of leptin (-8.25 ng/mL; p < 0.001), amylin (-21.3 pg/mL; p < 0.001), and glucagon-like peptide 1 (-59.55 pg/mL; p < 0.001). There was a small further reduction in leptin between 5% and 15% weight loss (-1.88 ng/mL; p = 0.019) but not in glucagon-like peptide 1 and amylin. Fasting ghrelin showed a significant increase at 10% weight loss (41.64 pg/mL; p = 0.002), with a nonsignificant increase from 10% to 15% loss (26.03 pg/mL; p = 0.065). Postprandial changes in hormone levels were variable. There was no correlation between baseline weight and the degree of hormone changes.
    Conclusions: The majority of changes in fasting gut hormones and leptin occurred in early weight loss, with minor further changes up to 15% weight loss. Starting weight did not affect the degree of hormone change.
    Mesh-Begriff(e) Appetite ; Body Mass Index ; Fasting ; Gastrointestinal Hormones ; Ghrelin ; Glucagon-Like Peptide 1 ; Humans ; Insulin ; Islet Amyloid Polypeptide ; Leptin ; Weight Loss
    Chemische Substanzen Gastrointestinal Hormones ; Ghrelin ; Insulin ; Islet Amyloid Polypeptide ; Leptin ; Glucagon-Like Peptide 1 (89750-14-1)
    Sprache Englisch
    Erscheinungsdatum 2022-03-06
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2230457-5
    ISSN 1930-739X ; 1071-7323 ; 1930-7381
    ISSN (online) 1930-739X
    ISSN 1071-7323 ; 1930-7381
    DOI 10.1002/oby.23404
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4061: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 87: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  10. Artikel ; Online: Endocrine aspects of obesity.

    Proietto, Joseph

    Molecular and cellular endocrinology

    2010  Band 316, Heft 2, Seite(n) 103

    Mesh-Begriff(e) Adult ; Body Mass Index ; Body Weight ; Child ; Endocrine System/physiology ; Humans ; Obesity/epidemiology ; Obesity/physiopathology
    Sprache Englisch
    Erscheinungsdatum 2010-03-25
    Erscheinungsland Ireland
    Dokumenttyp Editorial ; Introductory Journal Article
    ZDB-ID 187438-x
    ISSN 1872-8057 ; 0303-7207
    ISSN (online) 1872-8057
    ISSN 0303-7207
    DOI 10.1016/j.mce.2009.12.004
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1127: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang